IPO News Archive

Biotechnology firm Bioheart significantly cuts IPO deal size

10/12/02


Bioheart, a biotech company engaged in the development of autologous cell therapies for the treatment of chronic and acute heart damage, amended the terms for its planned IPO on Thursday. While the company now plans to offer roughly 4.2 million shares vs. 3.6 million shares as originally planned, it slashed its proposed price range from $14-$16 to $6-$8, according to the latest SEC filing. Timing for the IPO was pushed back to the week of October 22 by lead underwriter Merriman Curhan Ford & Co.

View IPO Profile: BHRT         
Source: www.RenaissanceCapital.com
Latest User Comments
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest